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ABSTRACT
The spinal dorsal horn receives a dense innervation of
noradrenaline-containing ﬁbers that originate from pontine
neurons in the A5, locus coeruleus (LC), and A7 cell groups.
These pontospinal neurons are believed to constitute a
component of the endogenous analgesic system. We used
an adenoviral vector with a catecholaminergic-selective
promoter (AVV-PRS) to retrogradely label the noradrenergic
neurons projecting to the lumbar (L4–L5) dorsal horn with
enhanced green ﬂuorescent protein (EGFP) or monomeric
red ﬂuorescent protein (mRFP). Retrogradely labeled neu-
rons (145  12, n  14) were found in A5-12%, LC-80% and
A7-8% after injection of AVV-PRS-EGFP to the dorsal horn
of L4–L5. These neurons were immunopositive for dopa-
mine -hydroxylase, indicating that they were cat-
echolaminergic. Retrograde labeling was optimal 7 days
after injection, persisted for over 4 weeks, and was depen-
dent on viral vector titer. The spinal topography of the nor-
adrenergic projection was examined using EGFP- and
mRFP-expressing adenoviral vectors. Pontospinal neurons
provide bilateral innervation of the cord and there was little
overlap in the distribution of neurons projecting to the cer-
vical and lumbar regions. The axonal arbor of the pontospi-
nal neurons was visualized with GFP immunocytochemistry
to show projections to the inferior olive, cerebellum, thala-
mus, and cortex but not to the hippocampus or caudate
putamen. Formalin testing evoked c-fos expression in these
pontospinal neurons, suggesting that they were nocir-
esponsive (A5-21%, LC-16%, and A7-26%, n  8). Thus, we
have developed a viral vector-based strategy to selectively,
retrogradely target the pontospinal noradrenergic neurons
that are likely to be involved in the descending control of
nociception. J. Comp. Neurol. 512:141–157, 2009.
© 2008 Wiley-Liss, Inc.
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The individual perception of pain may be dramatically inﬂu-
enced by the circumstances under which injury occurs (Wall,
1999). Thus, there are endogenous central neural mechanisms
that regulate the transmission of nociceptive information ac-
cording to the animal’s behavioral state when an injury oc-
curs. Since the initial report of electro-analgesia following
brainstem stimulation (Reynolds, 1969), much attention has
been focused on the mechanisms mediating the descending
control of nociception (Stamford, 1995; Millan, 2002; Lumb,
2004). The pontine noradrenergic cell groups (A5, A6 [locus
coeruleus, LC], and A7) are believed to form a key antinoci-
ceptive component of this system, as some of these neurons
project to the dorsal horn of the spinal cord (Westlund et al.,
1983) and release noradrenaline (NA) to suppress transmis-
sion of the pain message (Millan, 1997; Pertovaara, 2006).
Multiple strands of evidence support the role of the ponto-
spinal noradrenergic neurons in mediating an antinociceptive
action. Direct stimulation (electrical or chemical) of these NA
nuclei (A5–7) in anesthetized animals produces antinocicep-
tion (Jones and Gebhart, 1986a; Burnett and Gebhart, 1991;
Yeomans et al., 1992). Alpha-adrenoceptor antagonists have
been shown to block brainstem stimulation-evoked analgesia
(Miller and Proudﬁt, 1990) and indeed to cause hyperalgesia
under basal (unstimulated) conditions (Sagen and Proudﬁt,
1984). Similarly, ablation of the spinal NA projection with 6-OH
dopamine has been reported to produce acute hyperalgesia
(Fasmer et al., 1986). At a cellular level, extracellular record-
ings of dorsal horn nociceptive cells have shown LC stimula-
tion to decrease noxious heat-evoked ﬁring (Jones and Geb-
hart, 1986b). Intracellular recordings have shown that
application of NA inhibits dorsal horn neurons by both pre-
and postsynaptic actions at alpha2-adrenoceptors (North and
Yoshimura, 1984; Sonohata et al., 2004). The intrathecal ad-
ministration of alpha-adrenoceptor agonists is analgesic in
animals (Reddy et al., 1980; Reddy and Yaksh, 1980) and
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© 2008 Wiley-Liss, Inc.humans (Eisenach et al., 1998). Furthermore, a number of
clinically useful analgesics act by mimicking (clonidine/
dexmedetomidine) or enhancing (amitriptyline/tramadol/
duloxetine) the activity of the noradrenergic system.
This view of the pontospinal noradrenergic system has been
questioned following some recent experiments using intrathe-
cal administration of the toxin saporin conjugated to antido-
pamine -hydroxylase (DBH) antibodies to ablate the NA neu-
rons which did not demonstrate the expected pronounced
hyperalgesia (Martin et al., 1999; Jasmin et al., 2003a). This
may have been due to a number of factors, such as the loss of
noradrenergic neurons with projections to other brain regions
or compensatory responses to the loss of NA inputs. An
alternative possibility could be that the ablation of a system
capable of bidirectional modulation (Holden et al., 1999; Hedo
and Lopez-Garcia, 2001; Millan, 2002) could produce a subtle
net overall effect on nociception. Nonetheless, these ﬁndings
have lead Jasmin et al. (2003b) to call into question the hy-
pothesis that antidepressant analgesia (e.g., with amitripty-
line) is mediated by an effect on the NA system.
The brainstem NA neurons have large axonal arbors with
extensive collateralization that project to form a diffuse net-
work of terminals throughout the entire central nervous sys-
tem (CNS) (Dahlstrom and Fuxe, 1964; Palkovits and Brown-
stein, 1989). However, there is evidence of spatial speciﬁcity
in the organization of the NA system (Foote et al., 1983); for
example, the LC has a topographical organization and neu-
rons exhibit speciﬁc target ﬁelds, e.g., spinal cord, cerebel-
lum, hypothalamus, or cortex (Loughlin et al., 1986). Further-
more, the catecholaminergic innervation of the dorsal, ventral,
and lateral horns of the rat spinal cord is reported to originate
from the A7, LC, and A5 cell groups, respectively (Clark and
Proudﬁt, 1991a,b; 1993). This complex anatomical and func-
tional organization may account for some of the differences
seen between previous studies as a consequence of the dif-
ﬁculty of selectively activating or inactivating the pontospinal
noradrenergic component in isolation.
In order to selectively target the pontospinal noradrenergic
system, we have developed an adenoviral vector (AVV) strat-
egy. This takes advantage of the ability to retrogradely trans-
fect neurons using AVV and a catecholaminergic selective
promoter (PRS) (Hwang et al., 2001; Lonergan et al., 2005) to
drive expression of ﬂuorescent proteins in pontospinal norad-
renergic neurons. Using this technology, we have been able to
deﬁne the anatomical organization of the pontospinal norad-
renergic projection to the lumbar dorsal horn, which receives
peripheral inputs from the hindpaw, and have shown that
these neurons are activated following a persistent noxious
stimulus.
MATERIALS AND METHODS
Experiments were performed on 70 male Wistar rats (Uni-
versity of Bristol colony). All procedures conformed to the UK
Animals (Scientiﬁc Procedures) Act 1986 and were approved
by our institutional ethical review committee. Animals were
group-housed with an enriched environment under a standard
12-hour light/dark cycle, with free access to food and water.
Adenoviral vector construct and preparation
The AVV shuttle plasmids for AVV-PRS-EGFP and AVV-
PRS-mRFP were constructed by inserting the 240-bp PRSx8
promoter sequence (Hwang et al., 2001) upstream of EGFP
and mRFP sequences (Duale et al., 2005; Lonergan et al.,
2005). AVVs were obtained by homologous recombination
with helper plasmids and proliferation in HEK293 cells, fol-
lowed by CsCl gradient puriﬁcation, using standard tech-
niques (Graham and Prevec, 1995). The AVV stocks were
titered by an immunoreactivity “spot” assay (goat antihexon
antiserum, Biodesign International, Kennebunk, ME) accord-
ing to previously published protocols (Bewig and Schmidt,
2000; Duale et al., 2005) and titers were expressed in trans-
ducing units (TU) per mL.
Surgical procedures
Wistar rats (130–200 g) were anesthetized (i.m. or i.p.) with
ketamine (5 mg / 100 g, Vetalar, Pharmacia, Northampton-
shire, UK) and medetomidine (30 g / 100 g, Domitor, Pﬁzer,
Kent, UK) until loss of hindpaw withdrawal reﬂex. The animal
was placed in a stereotaxic frame and secured in atraumatic
ear bars. Core temperature was monitored using a rectal
thermistor and maintained at 37°C with a homeothermic blan-
ket (Harvard Apparatus, Kent, UK). Aseptic surgical tech-
niques were employed throughout.
Lumbar spinal exposure. The spinous process of T13
was identiﬁed by tracing the lowest rib to the vertebrae.
Through a midline incision, the paraspinous muscles were
detached from T12–L2 and a laminectomy was performed
using ﬁne rongeurs (Fine Science Tools, Heidelberg, Ger-
many) to allow access to the spinal cord at L4–5. The spinous
process of L3 was ﬁxed in a spinal clamp (Narishige, Tokyo,
Japan) to minimize movement during injections.
Cervical spinal exposure. The head of the rat was angled
down (incisor bar at 20 mm) and through a midline incision
the paraspinous muscles were parted to deﬁne the prominent
T2 spinous process that was clamped and axially distracted.
This allowed a laminectomy to be performed to expose the
dorsal aspects of C6–C7 segments of the spinal cord.
Adenoviral vector injection. Injections of AVV were made
using a microcapillary pipette (calibrated in 1 L intervals;
Sigma, St. Louis, MO), with a tip diameter of around 20 m. A
25 L syringe (Hamilton, Bonaduz, Switzerland) was con-
nected to the pipette with tubing primed with mineral oil.
Using a syringe driver (Genie; Kent Scientiﬁc, Litchﬁeld, CT)
the pipette was backﬁlled with AVV. The pipette was directed
into the dorsal horn using a micromanipulator (Narishige) to
coordinates 400 m lateral to the midline, 500 m deep to
dorsal surface. The successful delivery of AVV was visually
conﬁrmed on each occasion by observing the movement of
the oil-vector medium interface in the calibrated capillary.
Unless otherwise stated, two pairs of bilateral injections
(each 500 m apart in the rostrocaudal axis) of AVV (500
nL/injection over 2 minutes) were made into a single spinal
segment (Fig. 1).
Recovery. The paraspinous muscles were sutured and
the skin was closed with clips. Animals were given 1 mL sterile
saline (i.p.) for ﬂuid replacement, buprenorphine (2 g / 100 g
s.c., Temgesic, Schering-Plough, Hertfordshire, UK) for pain
relief and atipamezole (an alpha2-adrenoceptor antagonist,
0.1 mg / 100 g i.p., Antisedan, Pﬁzer) to reverse the medeto-
midine anesthesia. Animals were monitored in a recovery
room for the ﬁrst 24 hours following surgery.
Tissue ﬁxation. Rats were sacriﬁced (at 7 days, unless
otherwise stated) with an overdose of pentobarbital (20 mg /
The Journal of Comparative Neurology
142 P.W. HOWORTH ET AL.100 g i.p., Euthatal, Merial Animal Health, Essex, UK). After an
intracardiac dose of heparin (100 IU) the animal was perfused
transcardially with 0.9% NaCl (1 mL/g) followed by 4% form-
aldehyde (Sigma) in 0.1 M phosphate buffer (PB, pH 7.4, 1
mL/g). After perfusion the L4 and L5 dorsal root ganglia were
identiﬁed, marked, and their roots used as a reference for
segmental identiﬁcation of the spinal cord. The brain and
spinal cord were removed and postﬁxed for 2 hours before
overnight cryoprotection in 30% sucrose in 0.1 M PB. To
distinguish orientation the tissue was marked with a needle
puncture site.
Identiﬁcation of spinal injection sites
The spinal cord from rats at 1–14 day post-AVV injection
was cut in either coronal, longitudinal, or sagittal planes. The
injection tracks were typically visible allowing conﬁrmation of
the location of the injection site within the target area of the
dorsal horn. Immunocytochemistry for hexon protein, a com-
ponent of the adenoviral coat, determined the extent of
spread of the injected AVV. Examination of spinal cord tissue
at the earliest timepoint (24 hours after the injection) indicated
that the spread of AVV was conﬁned to the ipsilateral dorsal
horn (see Fig. 1). The expression of hexon viral protein was
seen in a reduced distribution at day 3, and by day 7 only a
“halo” region around the injection site (within 100 m) was
observed.
Immunohistochemistry
Tissue sections were cut at 40-m intervals using a freezing
microtome and either serially mounted or left free-ﬂoating for
ﬂuorescence immunohistochemistry (IHC). Mounted sections
were ringed with a DAKO pen (DAKO, Ely, UK) for on-slide
incubations. Tissue sections were washed (3) in 0.1 M
phosphate-buffered 0.9% NaCl (pH 7.4, PBS) and permeabil-
ized in 50% ethanol for 30 minutes before further washing.
The tissue was incubated with primary antibodies (see Table
Figure 1.
Retrograde targeting of brainstem noradrenergic neurons using spinal injection of AVV. a: Schematic of experimental approach. AVV-PRS-EGFP
is injected into the dorsal horn of the lumbar spinal cord. The AVV is taken up by axon terminals of the pontospinal noradrenergic neurons and
retrogradely transported. EGFP is expressed under the control of the catecholaminergic selective promoter PRS to enable visualization of the
neuronal anatomy. b: The location and depth of the injection site is indicated by hexon protein-immunoreactivity (Cy3 ﬂuorescence) in the spinal
cord (1 day after unilateral AVV-injection). c: Overlaid brightﬁeld and ﬂuorescence images shows the spread of the AAV to be limited to the dorsal
horn. Inset shows Rexed’s laminae, red line indicates the injection trajectory. Scale bar  100 m.
The Journal of Comparative Neurology
143 TARGETING PONTOSPINAL NORADRENERGIC NEURONS1) in PBS with 5% horse serum (HS), 0.3% Triton X-100, and
0.01% sodium azide for 24–72 hours at room temperature.
Mounted sections were kept in a humidiﬁed chamber (RA
Lamb, Eastbourne, UK) and free-ﬂoating sections were con-
tinuously agitated. After further washing, sections were incu-
bated overnight with biotinylated secondary antibody (all
Jackson ImmunoResearch, West Grove, PA; see Table 1) di-
luted 1:1,000 in PBS with 2% HS and 0.3% Triton. Sections
were washed, incubated with Streptavidin Cy3 (1:1,000 in
PBS, Sigma) for 4 hours before a ﬁnal wash. Additionally some
sections were incubated with DAPI (4,6-diamidino-2-
phenylindole dilactate, 1 g/mL, Invitrogen, La Jolla, CA) for
15 minutes to delineate the nucleus. Controls were routinely
run, by omitting primary antibodies, to ensure the speciﬁcity
of immunostaining.
For double labeling experiments to identify c-fos and DBH-
immunoreactive (-ir) neurons, sections were incubated with
anti-DBH (1:5,000) and anti-c-fos (1:2,000) in PBS with 5% HS,
0.3% Triton, and 0.01% sodium azide for 48 hours. Sections
were washed before overnight incubation with AMCA-
conjugated antimouse (1:100) and biotinylated antirabbit (1:
500) secondaries in PBS with 2% HS and 0.3% Triton. After
further washes, the tissue was incubated with Streptavidin
Cy3 (1:500 in PBS) for 4 hours.
The mouse monoclonal anti-DBH antibody (Chemicon, Te-
mecula, CA; MAB308) was raised against puriﬁed bovine DBH.
The distribution of labeled neurons within the brainstem
closely resembled that described for catecholaminergic neu-
rons reported by previous investigators in the rat (Dahlstrom
and Fuxe, 1964; Swanson, 1976; Grzanna and Molliver, 1980)
and speciﬁcally in studies using this particular antibody (Rina-
man, 2001; Espana and Berridge, 2006). In the absence of a
commercial source of puriﬁed bovine DBH, antibody speciﬁc-
ity was conﬁrmed using a previously described preabsorption
protocol (Dvoryanchikov et al., 2007). In brief, 1:10,000 dilu-
tions of the anti-DBH antibody were preincubated in wells at
room temperature either with or without a 40-m section of
ﬁxed rat adrenal medulla. The aliquots were then aspirated
and used in parallel according to the previously described IHC
protocol against serial sections of pontine tissue containing
the LC. The ﬂuorescence labeling of LC neurons was abol-
ished by the preincubation of antibody with the adrenal me-
dulla.
The anti-c-fos polyclonal rabbit IgG (Santa Cruz Biologicals,
Santa Cruz, CA; sc-52) was raised against a N-terminus pep-
tide from human c-fos (amino acids 3–16, sc-52P). This anti-
body recognized a 62-kDa protein, inducible by phorbol ester
application, on Western blot corresponding to the expected
molecular weight of c-fos (manufacturer’s technical
datasheet). The immunoreactivity for c-fos induced in re-
sponse to formalin testing was eliminated in both the spinal
cord and the locus coeruleus by overnight preabsorption of
the anti-c-fos antiserum with 0.1 g/mL of the peptide antigen
sc-52P.
The anti-GFP rabbit polyclonal IgG (Invitrogen, A11122) was
raised against GFP protein extracted from Aequorea victoria
and afﬁnity column puriﬁed; its speciﬁcity has been conﬁrmed
in rat neurons transfected with GFP-expressing vectors (Card
et al., 2006). In our control experiments no labeling was seen
in brain tissue from animals that had not been transfected with
AVV-PRS-EGFP.
The antihexon goat polyclonal IgG (Biodesign International,
B65101G) was raised against hexon protein from adenovirus
type 2 and also recognizes hexon from adenovirus types 5
and 6. It identiﬁes a protein of 105 kDa on Western blot
corresponding to the expected molecular mass of hexon pro-
tein (manufacturer’s technical datasheet). Speciﬁcity of this
antibody for our adenoviral vector was tested by preincuba-
tion of antihexon antibody (1:1,000) with Ad-PRS-EGFP (4 
10
9 TU/mL) overnight. Subsequent IHC using control and pre-
absorbed antihexon antibody (1:2,000) on serial sections of
spinal cord injection sites (24 hours after injection of Ad-PRS-
EGFP) showed that preabsorption eliminated the ﬂuores-
cence labeling surrounding the injection site.
Data analysis and photomicrography
All sections were mounted and coverslipped with ﬂuores-
cent mounting medium (DAKO). Tissue was examined and
representative images obtained using a conventional ﬂuores-
cence microscope (Zeiss Axioskop 2) or with a confocal mi-
croscope (Leica DMIRBE and TCSNT). Images were acquired
and processed using the respective company software (to
adjust contrast and brightness) and, if required, images were
further processed using Adobe Photoshop CS2 (Adobe Sys-
tems, San Jose, CA) to annotate structures and add scale
bars.
Retrogradely labeled pontospinal noradrenergic neurons
were counted as being present within each section when the
nucleus could be identiﬁed within the cell body and a primary
dendrite was visible. Counts of DBH-positive cells were made
TABLE 1. Antibodies
Primaries
Epitope Dilution Species Source Code/batch
Hexon 1:2,000 Goat Biodesign International, Kennebunk, ME B65101G/4A03106
DBH 1:10,000 Mouse Chemicon, Temecula, CA MAB308/24120144
c-fos 1:2,000 Rabbit Santa Cruz Biotechnology, Santa Cruz, CA sc-52/H0105
GFP 1:4,000 Rabbit Invitrogen, Paisley, UK A11122/56884A
CTb 1:2,000 Goat List Biological Labs, Campbell, CA 703-2A5
Secondaries (raised in donkey)
Anti- Tag Dilution Source Code
Mouse AMCA 1:100 Jackson, West Grove, PA 715-156-150
Rabbit Biotinylated 1:500-1,000 Jackson 711-066-152
Mouse Biotinylated 1:1,000 Jackson 715-066-150
Goat Biotinylated 1:1,000 Jackson 705-066-147
Goat Alexa 594 1:200 Invitrogen A-11058
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(n  2 rats) we obtained an accurate estimate for the size of
the nucleus in the retrogradely labeled NA neurons (9.6  0.6
m, n  32) and used this average dimension to Abercrombie
(1946) correct all NA neuron cell counts.
Data reported as mean  SEM. Statistical signiﬁcance was
assessed using unpaired t-test or one-way ANOVA with Bon-
ferroni’s post-hoc test (Prism4, GraphPad, San Diego, CA),
differences were considered signiﬁcant at P < 0.05.
Experimental protocols
Targeting noradrenergic neurons projecting to the lumbar
dorsal horn. To test whether the AVV could retrogradely
target the pontospinal noradrenergic neurons we injected
AVV-PRS-EGFP (3  10
10 TU/mL) bilaterally into the lumbar
(L4–5) dorsal horn of spinal cord (n  14). The spinal cord,
brainstem, and forebrain were examined for the presence of
EGFP-positive neurons (the morphology of the cell somata
was examined in detail in nine of these animals). DBH IHC was
used to examine whether the EGFP expression was restricted
to catecholaminergic neurons (n  6). An indication of the
relative contributions of each of the pontine NA nuclei to the
pontospinal projection was obtained from counts of DBH-
positive neurons in each region. These counts were deter-
mined directly for the A5 and A7 regions (n  3 rats) and we
used previously obtained values for the LC (Loughlin et al.,
1986). This allowed the calculation of the proportion of neu-
rons in each region that projected to the lumbar spinal cord.
We compared AVV-PRS-EGFP with the conventional retro-
grade tracers FluoroGold (FG, Fluorochrome, Denver, CO),
cholera toxin b subunit (CTb, List Biological Laboratories,
Campbell, CA), and red ﬂuorescent latex microspheres (Ret-
robeads, Lumaﬂuor, Naples, FL). For these experiments AVV
(3  10
10 TU/mL) was injected (at two sites bilaterally) into the
L4/L5 spinal cord (n  9 rats). To obtain an estimate of the size
of the total population of NA neurons projecting to the lumbar
spinal cord a pair of FG (5%, 50 nL each side, n  2 rats) or
CTb (1%, 500 nL, n  4 rats) injections was made into the
spinal dorsal horn, interleaved between the AVV injections.
We also made use of ﬂuorescent microspheres, which are
known to have a more restricted distribution from the injec-
tions site to identify the NA neurons projecting speciﬁcally to
the L4–5 dorsal horn (100 nL, at two sites bilaterally) inter-
leaved with the AVV injections in the rostrocaudal axis (n  3
rats). One further animal received co-injections (500 nL, two
sites bilaterally) of a mixture of AAV-PRS-EGFP (3  10
10
TU/mL) and red microspheres (1:2 dilution). For the CTb in-
jections retrogradely labeled brainstem neurons were de-
tected by IHC for CTb (1:2,000, 3 days at 4°C, goat anti-CTb,
List Biological Laboratories) and revealed by incubation with
ﬂuorescent secondary antibody (antigoat Alexa 594, 1:200,
overnight, Invitrogen). All brainstem tissue was processed for
DBH IHC to determine the numbers of noradrenergic neurons
labeled by FG/CTb/beads.
Factors inﬂuencing retrograde viral transduction.
Effect of AVV titer. AVV-PRS-EGFP was diluted with PBS
prior to spinal injection to obtain titers of 3, 30, 100 (n  3 per
group), 300 (n  14), and 1000  10
8 (n  3) TU/mL.
Inﬂuence of time postinjection on retrograde labeling.
AVV-PRS-EGFP (3  10
10 TU/mL) was injected into L4/L5 of
the dorsal horn. Rats (n  31) were divided into ﬁve groups
and culled at the following timepoints after injection: day 1 (24
hours, n  3), day 2 (n  3), day 5 (n  3), day 7 (n  14), and
day 14 (n  8).
AVV injection into lumbar cerebrospinal ﬂuid. To test
whether intraparenchymal delivery was required for retro-
grade labeling AVV-PRS-EGFP was injected intrathecally into
the cerebrospinal ﬂuid, over the lumbar dorsal horn (3  10
10
TU/mL, 2 L, n  2).
Topographical organization of the pontospinal noradren-
ergic projection. Injections of AVV-PRS-EGFP or -mRFP
were made into discrete locations within the spinal cord to
examine the topography of the pontospinal NA projection.
Spinal segmental organization of the noradrenergic projec-
tion. One group of rats (n  4) had a two-level laminectomy
(L4–5 and C6–7) and received bilateral injections of AVV-PRS-
EGFP or AVV-PRS-mRFP (1.2  10
10 TU/mL) into L4/L5 and
C6/C7 spinal segments (respectively). The control group (n 
3) had bilateral injections placed into the L4/5 spinal seg-
ments, of both AVV-PRS-EGFP and AVV-PRS-mRFP (both
1.2  10
10 TU/mL). The injection sites for each AVV were
interleaved within the same segment so that there was a
rostrocaudal distance of 250 m between successive injec-
tions sites (i.e., 500 m between consecutive AVV-PRS-EGFP
injection sites). We also examined the effect of bilateral co-
injection of AVV-PRS-EGFP and AVV-PRS-mRFP (both 8 
10
9 TU/mL, mixed in the same pipette) to the L4/L5 dorsal
horn (n  3).
Animals were culled 14 days after AVV injection. Retro-
gradely labeled brainstem neurons were counted and the
proportion of double-labeled cells was expressed as a per-
centage of the total number of mRFP-positive neurons.
Lateralization of pontospinal noradrenergic projection.
Rats (n  3) received four unilateral injections of AVV-PRS-
EGFP (3  10
10 TU/mL) into L4/L5 dorsal horn. The distribu-
tion of retrogradely labeled neurons (ipsi- vs. contralateral)
was expressed as percentage of the total number of neurons
in the A5, LC, and A7 groups.
Projections of pontospinal NA neurons to other brain re-
gions. The extent of the axonal arbor of the pontospinal NA
neurons that innervate dorsal horn of the L4/L5 spinal seg-
ments were revealed using anti-EGFP IHC. Rats (n  5) had
bilateral spinal injections of AVV-PRS-EGFP (3  10
10 TU/mL)
and were culled 14 days later. Brain tissue was cut in the
coronal plane, while spinal cord tissue was cut in coronal,
longitudinal, and sagittal planes. To contrast the pattern of
distribution of noradrenergic ﬁbers with the EGFP containing
projections from pontospinal neurons, alternate sections were
processed for anti-GFP and anti-DBH IHC (in two animals).
The density of the EGFP containing ﬁber projections revealed
by anti-GFP IHC was scored for each animal on a rating scale
from 0 to 5, with 0 representing a total absence of ﬁbers to 5
being densest (e.g., principal nucleus of the olive).
To test whether the pontospinal NA neurons had multiple
projection targets a further two animals received both lumbar
spinal injections of AVV-PRS-EGFP and injections of red ﬂu-
orescent beads (four unilateral injections of 100 nL) into sites
within the ventral posterolateral thalamic nucleus (micropi-
pette lowered vertically through a craniotomy burr hole to
injection sites located between bregma 2.3 to 3.5 mm, ML
3–3.6 mm, and depth 6–6.4 mm; coordinates after Paxinos
and Watson, 2005). Animals were culled 14 days after AVV and
bead injections. The bead injection sites were conﬁrmed as
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labeled neurons were counted in A5, LC, and A7 regions. The
proportion of bead and EGFP double-labeled cells was ex-
pressed as percentage of the total number of EGFP-positive
neurons.
Activation of pontospinal NA neurons during the formalin
test. All animals were handled daily and habituated to the
testing room, experimental equipment, and handlers. Rats
(n  10) received bilateral injections of AVV-PRS-EGFP (3 
10
10 TU/mL) into the L4/L5 dorsal horn. One week later the
animals were divided into two groups for the formalin test, a
test group (n  8) and a control group (n  2). Rats were
acclimatized for 30 minutes to a clear Plexiglas testing cham-
ber before either formalin (5% neutral buffered) or NaCl (0.9%)
was injected subcutaneously (50 L, 30G needle) to raise a
bleb on the dorsal surface of the right hindpaw.
Rats were replaced in the testing chamber and the numbers
of ﬂinches and foot lifts were tallied over 1-minute periods,
initially every 2 minutes for the ﬁrst 10 minutes and then every
5 minutes for the remainder of the 60 minutes. Animals were
culled 2 hours after the end of the observation period to allow
optimal c-fos expression. Brainstem tissue was processed for
c-fos and DBH IHC in all rats and counts were made of
retrogradely labeled pontospinal neurons showing c-fos ex-
pression across each cell group. In addition, spinal c-fos
expression was quantiﬁed (control [n  2] and formalin test
rats [n  3]) by tallying the positive neurons from 10 coronal,
nonsequential, spinal cord sections (40 m) from L4–5 with
the greatest numbers of c-fos positive nuclei. Comparisons
were made between c-fos counts in control and test group
animals and between ipsi- and contralateral dorsal horns.
RESULTS
Targeting noradrenergic neurons projecting to
the lumbar dorsal horn
Distribution of cell somata. Following spinal injection of
AVV-PRS-EGFP (3  10
10 TU/mL) into L4–L5 dorsal horn,
retrogradely labeled ﬂuorescent (EGFP-expressing) neurons
were only seen in the pontine A5, LC, and A7 areas (Fig. 2).
The total number of labeled pontine neurons at 7 days postin-
jection was 145  12 (n  14) with a majority in LC (115  10;
80%) and the remainder in A5 (18  2; 12%) and A7 (11  2;
8%, Fig. 2d). Labeled somata were scattered throughout the
LC, but with a higher density in the ventral pole of the nucleus.
The strength of EGFP expression in the pontospinal neurons
allowed clear visualization of the soma and proximal dendritic
arbor. Examination of LC cell morphology (from nine rats)
showed the majority of retrogradely labeled somata were fusi-
form (70  3%), with the remainder being multipolar (24  3%)
or round (6  1%).
The retrogradely labeled neurons showed DBH-ir (A5, 97 
3%; LC, 97  4%; and A7, 100  0%, n  6, see Fig. 3),
indicating that the PRS promoter restricted the expression of
EGFP to catecholaminergic neurons. The retrogradely labeled
LC neurons that we were unable to unequivocally determine
as being DBH-ir (1.6%, 10/622, n  6 rats) were found in the
core of the nucleus and had morphologies consistent with
being noradrenergic. However, because of the density of DBH
staining seen in the closely packed cells in the core of the LC
it was occasionally difﬁcult to distinguish unequivocally be-
tween low ﬂuorescence signal in the labeled cell and that from
adjacent somata. Given the location of these cells within the
core of the LC, it would seem likely that they represent NA
neurons with faint DBH-ir.
The A5 and A7 regions were identiﬁed using the Paxinos
and Watson atlas (2005) and the total numbers of DBH-ir
neurons were counted in A5 (1553  337, n  3) and A7 (346 
43, n  3). The number of DBH-positive neurons in the LC
(3268  114) was taken from previous work (Loughlin et al.,
1986). Hence, it was possible to determine the proportionate
distribution of somata retrogradely labeled from L4–5 in each
of these cell groups expressed as a percentage of the total
number of NA neurons in each area (A5, 1.4  0.2%; LC, 4.4 
0.4%; and A7, 4.0  0.6%, n  14 rats).
Spinal co-injections of AVV-PRS-EGFP and FluoroGold (FG)
or CTb were used to compare the viral vector with conven-
tional retrograde tracers. Both FG and CTb demonstrated
numerous retrogradely labeled neurons throughout the brain-
stem, including DBH-positive neurons in the A5, LC (predom-
inately ventral) and A7 regions (FG: A5, 184  37, LC, 244  8,
A7, 61  10, n  2 rats; CTb: A5, 68  18, LC, 161  51, A7,
47  21, n  4 rats) and also in the rostral ventrolateral
medulla. Examination of the spinal cord after injection re-
vealed an extensive spread of both FG and CTb from the site
of injection with dispersion over many millimeters in the ros-
trocaudal axis and extension through the full thickness of the
cord to the ventral horn. This extensive spread of tracer would
be expected to have labeled neurons projecting to most of the
lumbar spinal enlargement as compared to the AVV, which
had more spread within restricted to the dorsal horn of two
segments (to a 300 m radius, Fig. 1). It should also be noted
that there was no pontine EGFP expression seen in the FG/
CTb experiments, indicating an apparent incompatibility in the
use of these conventional tracers with our adenoviral vector
(as suggested previously for FG: Schramm, 2006).
The spinally injected red latex microspheres showed a sim-
ilar restricted distribution in the cord to the AVV-PRS-EGFP
(n  3). Within the pontine NA nuclei the beads and AVV-PRS-
EGFP labeled similar numbers of neurons (78  25 vs. 110 
49 respectively, n  3, NS). Most of the bead-positive neurons
in the A5, LC, and A7 areas were DBH-positive (82%). The
distribution of bead-positive neurons across the NA cell
groups was essentially identical to that seen with the viral
vector with most located in the LC (79%) and the remainder in
A5 (15%) and A7 (5%). The interleaved injections (n  3 rats)
showed 18  4% double labeling of EGFP neurons with
beads. By contrast the co-injection of AVV with beads showed
60% colocalization (n  1 rat, note there was an apparent loss
of efﬁcacy of AVV labeling with this co-injection approach with
only 10 neurons being EGFP-positive).
Factors inﬂuencing retrograde AVV transduction
Effect of AVV titer. The efﬁciency of retrograde labeling
was dependent on the titer of AVV injected into the spinal
cord. Serial dilution of the AVV injectate produced reductions
in the numbers of retrogradely labeled neurons (see Fig. 4a)
from 145  12 (300  10
8 TU/mL, control) to 49  19 (at 100 
10
8, P < 0.0001) and down to as few as 5  3 (at 3  10
8
TU/mL). Interestingly, at the highest AVV titers (1,000  10
8
TU/mL) there was a dramatic fall in the numbers of retro-
gradely labeled neurons.
The Journal of Comparative Neurology
146 P.W. HOWORTH ET AL.Inﬂuence of time postinjection. The ﬁrst pontine retro-
grade labeling could be seen 24–48 hours after spinal injec-
tion of AVV-PRS-EGFP (Fig. 4b). The numbers of labeled pon-
tine neurons increased with longer expression periods up to
day 7, when it peaked and no further increase in the numbers
of EGFP-positive neurons was seen at day 14. The visible
extent of the dendritic tree of labeled neurons appeared
greater at day 14 compared to that seen at earlier timepoints,
suggesting the presence of higher concentrations of EGFP in
the processes.
AVV injection into lumbar cerebrospinal ﬂuid. One week
after intrathecal injection of AVV-PRS-EGFP (2 L, 3  10
10
TU/mL, n  2 rats) no EGFP-positive neurons were seen in the
pons or elsewhere in the brain or spinal cord, indicating that
intraparenchymal spinal injection of this AVV is needed for
retrograde labeling and importantly that the pontine labeling is
not a consequence of rostral spread of vector carried in the
CSF.
Topographical organization of the pontospinal
noradrenergic projection
Unilateral spinal injection of AVV demonstrated a bilateral
projection from the LC with an ipsilateral predominance (62 
4% of the labeled pontospinal NA neurons being ipsilateral,
n  3 rats; P < 0.05, unpaired t-test). Some of the pontospinal
neurons (4%) were seen to project bilaterally to the lumbar
dorsal horn using ipsi- and contralateral injections of AVV
expressing EGFP or mRFP (see Fig. 5).
Spinal segmental organization of noradrenergic projection.
The spinal segmental organization of the NA projection was
examined using injections of AVV-PRS-EGFP and AVV-PRS-
mRFP into the dorsal horn at different spinal levels (C6–7 and
L4–5). This showed sparse double labeling of neurons, with
only 1.3  1.0% of mRFP-positive LC neurons also expressing
EGFP (across all the pontospinal NA neurons only 1.0  0.8%
showed colocalization, n  4 rats). This contrasted with the
Figure 2.
Retrograde labeling of pontospinal neurons in A5, LC, and A7. Retrogradely labeled pontine neurons following transduction of the L4-5 dorsal
horn with AVV-PRS-EGFP. Fluorescent neurons are seen in locus coeruleus (a),A 5(b), and A7 (c) regions. Overlaid brightﬁeld and ﬂuorescence
images (a–c) with inset overlaid ﬂuorescence confocal stacks. d: Distribution of pontospinal neurons projecting to L4–5 dorsal horn. Following
administration of AVV-PRS-EGFP to the lumbar dorsal horn an average of 145  12 (n  14) retrogradely labeled neurons were found in the pons.
The majority of the cell somata were found in the locus coeruleus with the remainder in A5 and A7 clusters. (Data shown mean  SEM). 4V, 4th
ventricle, 7n, facial tract. Scale bars  1,000 m in a,c; 500 mi nb ;8 0m in all insets.
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comparison group that received injections of each AVV placed
into adjacent sites (placed 250 m apart) within the L4/L5
segment. Also, lumbar spinal co-injection from a single pi-
pette of AVV-PRS-EGFP and AVV-PRS-mRFP, mixed in equal
titers, showed that 62  3% (n  3) of all mRFP-positive LC
neurons expressed EGFP.
Axonal projections of pontospinal NA neurons
Using GFP IHC it was possible to amplify the EGFP ﬂuores-
cence signal and reveal ﬁne, distal processes (including axon
terminal ﬁelds) of the retrogradely labeled pontospinal NA
neurons throughout the neuroaxis (Figs. 6, 7; Table 2 for more
details). DBH IHC allowed comparisons to be made with the
Figure 3.
Retrogradely labeled neurons are catecholaminergic. Confocal stack images showing (a) EGFP-positive retrogradely labeled neurons in rostral
A7 region, (b) DBH-ir showing the cluster of A7 neurons (Cy3 red ﬂuorescence), and (c) overlay of confocal stack images conﬁrming all
EGFP-positive neurons are DBH-positive (d) darkﬁeld image with overlaid ﬂuorescence showing relative position of A7 neurons (bregma 8.4
mm). m5, motor root of the trigeminal nerve, mcp, middle cerebellar peduncle. Magenta-green copy available as Supplementary Figure 1. Scale
bars  80 mi na – c ;1 0 0mi nd .
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cord and conﬁrmed the GFP containing ﬁbers to be DBH-
positive.
Spinal cord. In the spinal cord, axonal projections, ﬁne
axonal branches, and terminal ﬁelds (Fig. 7a; Table 2) could be
observed. In transverse sections of L4/L5, there was dense
GFP-ir in the superﬁcial dorsal horn (SDH, laminae I and II),
moderate density of axonal projections in the deep dorsal
horn (DDH, laminae III–V) and the ventral horn (laminae VII–IX).
Moderate to dense labeling was observed around the central
canal (area X). The densest GFP-ir labeling in the white matter
of the spinal cord was found in the ventral funiculus, with light
to moderate labeling in the lateral funiculus and gracile fas-
ciculus. This pattern was conﬁrmed in the longitudinal and
sagittal sections, where long segments of GFP-ir axons were
observed running close to ventral, lateral, and dorsal surfaces,
with the majority observed in the ventral funiculus. Occasion-
ally, these axons could be seen to send collaterals at right
angles to project into the gray matter (see Fig. 7b).
Brain. In the telencephalon, light to moderate GFP-ir was
observed in the neocortex (particularly in the cingulate, fron-
tal, insula, and piriform areas) and globus pallidus. By con-
trast, relatively few axonal projections were observed in the
hippocampus, caudate putamen, nucleus accumbens, and
entorhinal cortex despite strong DBH-ir labeling. In the dien-
cephalon the highest density of GFP-ir was observed in thal-
amus. However, in the hypothalamus only light to moderate
GFP-ir was observed, in contrast with the strong DBH-ir.
In the cerebellum there was a moderate density of GFP-ir
labeling compared to the denser DBH labeling. The brainstem
showed moderate to dense GFP-ir staining, especially in the
inferior olive, pontine nuclei, periaqueductal gray, paramedian
raphe, ventral tegmental area, deep mesencephalic, and an-
terior pretectal nucleus. The GFP-ir in the inferior olive was
strongest in the principal nucleus.
To test whether these divergent projections originated from
the pontospinal NA neurons we combined spinal AVV-PRS-
EGFP with injections of red ﬂuorescent beads into the VPL
nucleus of the thalamus, a territory that we had noted to have
a dense projection of EGFP-containing ﬁbers. These thalamic
injections retrogradely labeled neurons in the core of the LC
and double labeling with beads was seen in 26  3% of the
EGFP-positive pontospinal NA neurons (n  2, Fig. 8). No
retrograde bead labeling at all was seen in the A7 region and
few neurons were seen in the A5 region with no double label-
ing of pontospinal neurons.
Activation of pontine-lumbospinal NA neurons
during noxious stimuli/formalin test
Rats transfected with AVV-PRS-EGFP showed typical bi-
phasic nociceptive behavioral responses (ﬂinching, paw lift-
ing, and licking) to formalin testing (n  8 rats, see Fig. 9a).
Injection of formalin compared to saline produced an ipsilat-
eral increase in the expression of nuclear c-fos in the super-
ﬁcial (140  55 [n  3] vs. 1  1[ n 2] positive nuclei per 10
sections, respectively) and deep dorsal horn (135  66 [n  3]
Figure 4.
Factors inﬂuencing efﬁciency of retrograde labeling. a: The titer of AVV-PRS-EGFP injected to the spinal cord was varied from 3–1,000  10
8
TU/mL (n  3 in each group, except 300 where n  14). Efﬁcient retrograde labeling required higher viral titers (>100  10
8 TU/mL). However,
at the highest AVV titer (1,000  10
8 TU/mL) the numbers of EGFP-positive neurons fell sharply. b: Time-course of retrograde transduction by
AVV-PRS-EGFP was examined by varying the duration of survival following spinal AVV injection. Signiﬁcant numbers of ﬂuorescent retrogradely
labeled pontine neurons were ﬁrst seen at day 2 after AVV injection and there was a steady increase in the numbers until day 7, when a plateau
was reached (n  3 for each group except day 7 [n  14] and day 14 [n  8]). (Means  SEM, one-way ANOVA with Bonferroni’s multiple
comparison test, *P < 0.05, **P < 0.01, ***P < 0.0001.)
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Formalin increased the brainstem expression of c-fos-ir in the
periaqueductal gray, the parabrachial nucleus, as well as in the
pontine noradrenergic cell groups (n  8). Signiﬁcantly more of
the retrogradely labeled pontospinal NA neurons showed
c-fos-ir expression after formalin compared to saline control
(18% vs. <1% of neurons, n  8 and 2 rats, respectively, P <
0.001, see Fig. 9b). The proportions of c-fos-positive pontospinal
NA neurons were relatively similar across all of the pontine cell
groups (A5, 21%, LC, 16%, and A7, 26%, n  8, see Fig. 9c).
DISCUSSION
In this study we demonstrated the ability of an AVV contain-
ing a catecholaminergic cell-speciﬁc promoter to selectively
retrogradely target pontospinal noradrenergic neurons pro-
jecting to the lumbar dorsal horn. This retrograde targeting
from the lumbar L4–5 segment identiﬁes a relatively small
pool (around 4%) of the total number of pontine noradrenergic
neurons in the LC and A7 areas (and <2% of A5). Using this
vector to express ﬂuorescent markers such as EGFP and
immunohistochemistry we have obtained a Golgi-like visual-
ization of the anatomy and projections of the pontospinal
noradrenergic neurons. Furthermore, we have been able to
show that these pontospinal noradrenergic neurons are acti-
vated (express c-fos) during a noxious stimulus applied to the
hindpaw, suggesting that these are nociresponsive and are
therefore likely to constitute a component of the descending
antinociceptive control system (Jones, 1991; Millan, 1997,
2002; Pertovaara, 2006).
Organization of the pontospinal noradrenergic
system
In agreement with a number of previous studies, we have
shown that the dense noradrenergic innervation of the dorsal
Figure 5.
Locus coeruleus neurons with bilateral projections to the spinal cord. Ipsi- (AVV-PRS-EGFP) and contra- (AVV-PRS-mRFP) lateral injections of
AVV and were made into the dorsal horn of L4/L5 to examine the topography of the projection of the pontospinal NA neurons. The colocalization
of ﬂuorophores (a) EGFP and (b) mRFP indicated neurons which projected bilaterally (white arrows, 4% of total) from the locus coeruleus to the
spinal cord ((c), overlay). Magenta-green copy available as Supplementary Figure 2. Scale bars  50 m.
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Demonstration of ﬁne processes. Confocal stack images of a sagittal section showing an EGFP-positive neuron in the ventral pole of the LC (a)
native EGFP ﬂuorescence (b) GFP immunoreactivity (Cy3 labeling) produced an enhanced visualization of the ﬁne dendritic and axonal
processes of the neuron (c) overlay image; inset shows position of neuron within LC (DBH-ir AMCA, blue). Magenta-green copy available as
Supplementary Figure 3. Scale bars  80 m, inset 100 m.
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the pontine A5, LC, and A7 regions (Westlund et al., 1983;
Fritschy and Grzanna, 1990; Clark and Proudﬁt, 1991a,b,
1993). In total, our viral vector identiﬁes around 150 pontine
neurons with terminal projections to the L4–5 dorsal horn.
Previous ablation studies using intrathecal administration of
anti-DBH-saporin showed loss of the majority of neurons in
LC (Jasmin et al., 2003a). However, those authors concluded
that their toxin had spread in the CSF to reach higher centers
such as the cortex, thus lesioning a large proportion of the NA
neurons. The AVV-PRS-EGFP by contrast requires intraparen-
chymal administration to target the pontospinal neurons so
there is no spread in the CSF to higher centers.
The majority of our retrogradely labeled neurons were lo-
cated in LC (80%), with the remainder in A5 (12%) and A7
(8%). This suggests that the predominant source of the neu-
rons projecting to the dorsal horn is the LC. However, when
considered as a proportion of the total number of noradren-
ergic neurons in each nucleus, the distribution becomes more
even across the pontine nuclei LC (4.4%) and A7 (4%) and
with relatively fewer in A5 (1.4%). These proportions suggest
that the LC and A7 nuclei may have topographical organiza-
tions with similar weightings for the hindlimb spinal segments.
Our adenoviral vector strategy identiﬁed comparatively
fewer pontospinal noradrenergic neurons than chemical ret-
rograde tracers (FG/CTb injected into the same region of the
spinal cord) with 50–70% the number of LC neurons (115 
10 [AAV] vs. 244  8 [FG] or 161  51 [CTb]) and relatively
smaller proportions of neurons in the A5 and A7 areas. It
should be noted, however, that both FG and CTb spread
considerably further within the cord parenchyma than the AVV
to extend several segments rostrocaudally and throughout the
full dorsoventral extent of the cord, thus they are likely to have
labeled the pool of NA neurons projecting to the lumbar en-
largement. In particular, the intermediolateral cell column,
which terminates at L2, would have been included in the ﬁeld
of the conventional tracer injection but not in our AVV injec-
tions. This may account for the differences in the relative
distribution of retrogradely labeled neurons across the NA
nuclei, particularly in the case of the A5 region (and in the
rostral ventrolateral medulla,) which have prominent projec-
tions to the sympathetic preganglionic neurons in the inter-
mediolateral cell column (Loewy et al., 1979). In addition, it
seems likely that our viral vector is only taken up by axon
terminal ﬁelds (see below and Ridoux et al., 1994; Liu et al.,
1997b), unlike FG or CTb, which are known to be taken up by
axons of passage and therefore are likely to label noradren-
ergic neurons with projections traveling to more caudal spinal
targets. By contrast, retrograde labeling with ﬂuorescent latex
microspheres (whose distribution was more limited in the
spinal cord) identiﬁed comparable numbers of neurons as the
AVV in the pontine A5, LC, and A7 areas with a similar pro-
portional distribution across these nuclei. Hence, it would
appear that dorsal horn injections of our AVV produces focal
transduction of the NA projection neurons that is of compa-
rable efﬁcacy to conventional tracers and, based on these
ﬁndings, we have no reason to believe that our AVV is selec-
tively targeting a speciﬁc subgroup of the pontospinal neu-
Figure 7.
Axonal labeling in spinal cord. In the spinal cord, terminal labeling was revealed using anti-GFP IHC (Cy3 ﬂuorophore, red). a: Lumbar dorsal
horn showing a predominance in the superﬁcial dorsal horn. b: Longitudinal sections (plane indicated by lines on inset) revealed axons
projecting in the lateral and ventral funiculi (white arrows). Bifurcations were occasionally observed projecting into the gray matter of the spinal
cord. Scale bars  80 m, inset 20 m.
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1980; Loughlin et al., 1986), we ﬁnd that these pontospinal
projections originate from a limited subset of the total popu-
lation of NA neurons.
The topography of the pontospinal projection was charac-
terized using AVVs expressing either EGFP or mRFP. This
showed that the noradrenergic projection to the cord from the
pons is bilateral, with an ipsilateral predominance (62%) in
agreement with previous functional studies showing bilateral
analgesic effects from unilateral stimulation of LC (Jones and
Gebhart, 1986b). A proportion of LC neurons were found to
have bilateral projection ﬁelds (at least 4% of the pontospinal
neurons). We found relatively little overlap in the neurons
projecting to the cervical and lumbar spinal dorsal horn (L4–5
and C5–6, 1% colocalization). By contrast, co-injection of the
vectors (or ﬂuorescent microspheres) in the same sites in the
lumbar spine produced 60% colocalization. This indicates
that there is a rostrocaudal topographical organization of the
pontospinal noradrenergic projection, with little overlap in the
populations of neurons innervating spinal territories receiving
sensory inputs from the fore- and hindlimbs. In addition, the
fact that we observed little double labeling when making com-
bined AVV injections to lumbar and cervical cord suggests
that the AVV is only retrogradely transported from the terminal
axonal ﬁeld rather than by axons of passage (unlike conven-
tional retrograde tracers). This makes the AVV a particularly
selective tool for retrograde targeting.
We noted that the EGFP expression allowed the axons of
the NA neurons to be identiﬁed and this could be enhanced by
IHC to give a Golgi-like visualization of distal projections (note
there was no increase in the numbers of GFP-positive labeled
noradrenergic cell bodies after this immuno-enhancement). A
similar ability to deﬁne the axonal processes of medullary NA
neurons of the (C1 group) has been reported using direct
injection of a lentiviral vector employing the PRS promoter to
drive EGFP expression (Card et al., 2006). We found that the
pontospinal neurons showed the expected pattern of axon
terminal ﬁelds in the spinal cord. When comparing the density
of the EGFP-containing ﬁbers with those revealed by DBH IHC
it was apparent that even in territories with relatively dense
EGFP-containing projections (such as the superﬁcial dorsal
horn) there was a greater density of DBH-containing ﬁbers.
Given the distance of these axonal terminals from the NA
somata, where the EGFP synthesis occurs, this disparity is
likely to be a consequence of a concentration threshold effect
for the visualization of EGFP-containing axons by immunocy-
tochemistry.
Interestingly, axonal projections from the pontospinal NA
neurons were also seen in other regions of the neuroaxis, such
as the inferior olive, periaqueductal gray, cerebellum, thala-
mus, and some regions of the cortex (insular, cingulate, and
piriform). Using the injection of ﬂuorescent microspheres to
the thalamic VPL we were able to retrogradely label neurons in
the LC (as has been previously shown; Simpson et al., 1997;
Voisin et al., 2005) and the presence of double labeling con-
ﬁrmed that some pontospinal LC neurons also project to the
thalamus. We found no evidence of double labeling of ponto-
spinal A5 or A7 neurons from the VPL. The distribution pattern
of EGFP-containing ﬁbers from the pontospinal neurons was
speciﬁc, as there was no projection seen to some regions that
have a dense noradrenergic innervation (DBH IHC), such as
the hippocampus, caudate putamen, nucleus accumbens,
and entorhinal cortex. This restricted distribution is in agree-
ment with previous ﬁndings showing a topographical organi-
zation of the neurons in LC (Loughlin et al., 1986). The distrib-
uted nature of the NA system and the lack of conventional
synaptic terminals (Descarries et al., 1977) have led to the
inference that these neurons exert a diffuse global effect
whose synchronized activation is important for generalized
phenomena such as arousal (see Dismukes, 1977). However,
the anatomical organization of the NA neurons projecting to
the spinal cord suggests that they exert inﬂuence over a
limited range of neural territories that share common func-
tional speciﬁcity, e.g., pain matrix (insular and cingulate cor-
tices, thalamus, periaqueductal gray, parabrachial nucleus,
and spinal dorsal horn) or motor control (cerebellum, thala-
mus, and inferior olive).
Methodological considerations
In agreement with previous studies, we have shown AVV to
be capable of retrograde transduction of neurons (Akli et al.,
1993; Ridoux et al., 1994; Liu et al., 1997b; Lonergan et al.,
2005; Tomioka and Rockland, 2006). Following spinal injection
of the AVV, EGFP-positive pontine neurons were ﬁrst seen
after 2–3 days and labeling was maximal at 7 days. Efﬁcient
retrograde labeling required higher titers of spinal AVV (>10
10
TU/mL). However, above this level a signiﬁcant fall-off was
seen in the numbers of transfected pontine neurons, perhaps
because local spinal reactions around the injection site dam-
aged axon terminals before transduction could be initiated.
Such an inﬂammatory effect has been previously reported
TABLE 2. Axonal Projection Targets of Pontospinal Noradrenergic Neurons
Brain region Area Density
Neocortex Cingulate 3
Frontal 3
Insular 3
Piriform 3
Entorhinal 1
Striatum Globus pallidus 3
Caudate putamen 1
Nucleus accumbens 1
Hippocampus CA1-CA3 0
Dentate gyrus 0
Basal Ventral pallidum 1
Forebrain
Thalamus Anteroventral nucleus 5
Anterodorsal nucleus 5
Mediodorsal nucleus 3
Reticular nucleus 5
Ventrolateral nucleus 5
Ventroposterior nucleus (medial and lateral) 5
Paratenial nucleus 2
Habenular nuclei 3
Hypothalamus Medial wall of paraventricular nucleus 3
Lateral hypothalamus 3
Cerebellum Molecular layer 3
Granular layer 3
Midbrain Periaqueductal gray 4
Hindbrain Pontine Nuclei 5
Parabrachial nucleus 3
Inferior olive
-principal nucleus 5
-medial nucleus 2
-dorsal nucleus 2
Spinal Cord Lumbar (L4-5)
-SDH (laminae 1-2) 5
-DDH (laminae 3-6) 3
-VH (laminae 7-9) 3
-Central canal (Area X) 4
-Ventral funiculus 4
-Lateral funiculus 2
-Gracile funiculus 2
Distribution of projections from pontospinal noradrenergic neurons demonstrated with
GFP-ir. Density of GFP-ir ﬁbres in each region on scale 0-5 (where 0absent, 1sparse
and 5dense).
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et al., 1997b).
The cell-speciﬁc promoter PRS successfully restricted ex-
pression of EGFP to pontine noradrenergic neurons as shown
by DBH IHC. Previous spinal administration of AVV with the
cytomegalovirus promoter has shown labeling of brainstem
neurons in the red nucleus, vestibular nuclei, within the pon-
tine reticular formation, and the locus coeruleus (Liu et al.,
1997b). By contrast, we only saw expression in the A5, LC,
and A7 cell groups with the PRS promoter. There is evidence
that the PRS promoter is active in noncatecholaminergic neu-
rons that express the Phox2 transcription factor, such as
cholinergic autonomic neurons in the brainstem in areas like
the dorsal vagal motor nucleus (Tiveron et al., 1996; Brunet
and Pattyn, 2002; Lonergan et al., 2005). Following spinal
administration of AVV-PRS-EGFP, we saw no expression in
these brainstem cholinergic groups, as they do not project to
the spinal cord. Furthermore, the spinal motoneurons and
sympathetic preganglionic neurons, which are cholinergic, do
not express the Phox2 transcription factor (Tiveron et al.,
1996) and we saw no expression of EGFP in these cell groups
following viral injection.
It is worth noting that following spinal injection of AVV the
rats showed a prompt recovery of motor and sensory func-
tion, such that their rotarod test was normal, as were their
responses to thermal and mechanical sensory stimuli applied
to the hindpaw (unpublished observation). Furthermore, rats
transfected with AVV-PRS-EGFP showed typical biphasic no-
ciceptive behavioral responses to formalin testing. Thus, our
spinal dorsal horn injections of AVV were not associated with
discernable gross motor or sensory deﬁcits. Also, within the
brainstem the retrograde transduction with AVV of the NA
neurons appeared to be well tolerated. These neurons are
capable of producing increased levels of c-fos following nox-
ious stimulation. We saw no change in the numbers of labeled
pontine NA neurons at timepoints of up to 1 month, indicating
that there was no cell death as a consequence of AVV trans-
duction and that the gene product continues to be transcribed
for this time period. This is in contrast to the experience with
high titers of AVVs when used by direct injection into the
target cell groups where gene expression appears short-lived,
in part because of local immune activation (Thomas et al.,
2001; Kugler et al., 2003). We have also made electrophysio-
logical recordings from transfected LC cells in both acute
slices and also in slice cultures of the pons (unpublished
observation) and the neurons appear healthy with ﬁring pat-
terns and intrinsic conductances similar to those previously
reported (Williams and Marshall, 1987).
Figure 8.
Pontospinal NA neurons can be double-labeled from the ventral posterolateral thalamic nucleus. Animals received microinjections of AVV-EGFP
to the dorsal horn at L4/L5 and red ﬂuorescent beads (4  100 nL) targeted to the thalamic VPL. a: Representative VPL injection site (overlaid
ﬂuorescence and darkﬁeld image) and schematic (adapted from Paxinos and Watson, 2005) showing injection track (dashed line). b: Within the
LC (shown overlaid on darkﬁeld image) there were numerous labeled neurons identiﬁed retrogradely from spinal cord (EGFP) and/or thalamus
(red beads). c–e: Confocal stack images of the LC (from boxed area in b) showing examples of retrogradely labeled EGFP-positive and red
beaded neurons (arrows), with two neurons showing colocalization (e, white arrows). Magenta-green copy available as Supplementary Figure
4. VPL, ventral posterolateral nucleus; LC, locus coeruleus; CB, cerebellum; 4V, 4th ventricle. Scale bars  500 m in a,b; 25 mi nc – e .
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of useful features compared to conventional neuroanatomical
tracing techniques. Through the use of cell-speciﬁc promoters
it is possible to express the gene of interest selectively in a
particular phenotype of cell, e.g., neuronal or glial (Lonergan
et al., 2005; Card et al., 2006). Furthermore, there are a number
of different ﬂuorophores (e.g., EGFP or mRFP) or histochem-
ical markers (i.e., beta-galactosidase) that can be expressed
and used to label different cell populations using the same
type of viral vector and promoter system. They also have the
potential to allow anatomically targeted functional manipula-
tions through the expression of genes that alter neuronal
function (Johns et al., 1999). In the exploration of the norad-
renergic system, this could simply be an extension of the
lesion experiments, which have used either metabolic toxins
such as DSP4 (Zhong et al., 1985) or immuno-toxins such as
anti-DBH-saporin (Zhong et al., 1985; Martin et al., 1999; Jas-
min et al., 2003a). However, the major advantage of the viral
vectors is that they can allow manipulations to up- or down-
regulate speciﬁc neuronal functions without ablating the neu-
rons of interest (e.g., Lechner et al., 2002; Duale et al., 2007).
Functional activation
To examine the role of the pontospinal NA neurons in noci-
ception, we employed the formalin test (Dubuisson and Den-
nis, 1977) as a model of a persistent acute pain, as it has
previously been shown that the endogenous NA analgesic
system is actively involved in attenuating the response to this
stimulus (Sugimoto et al., 1986; Liu et al., 1997a; Omote et al.,
1998). It has also been shown that LC NA neurons show
increased expression of c-fos in response to noxious stimu-
lation such as hindpaw injections of formalin (Baulmann et al.,
Figure 9.
Activation of pontine lumbospinal NA neurons during the formalin test. a: Assessment of the nociceptive behavioral response to formalin (red
squares) or control saline (blue circles) injected to the hindpaw in rats transfected with spinal AVV-PRS-EGFP. The response was quantiﬁed by
counting the number of ﬂinches and foot lifts each minute (every 2 minutes for the ﬁrst 10 minutes, then every 5 minutes for the remainder of
the test). Transfected animals showed typical biphasic behavioral response to the formalin injection. b: Pontine-lumbospinal NA neurons
express c-fos following the formalin test. After the completion of the formalin test pontine tissue was processed to reveal c-fos-ir and DBH-ir.
(i) A5 neurons revealed by the DBH stain (AMCA, blue). (ii) Annotated ﬁgure indicating location of cells (blue box, bregma 10.32 mm; Paxinos
and Watson, 2005). (iii) One of the A5 neurons is retrogradely labeled (EGFP). (iv) Several neurons show nuclear c-fos-ir (Cy3, red) and from the
overlay. (v) It is seen that the pontospinal neuron and several other DBH-positive neurons (white arrows), are c-fos-positive. 7n, facial nerve tract,
SO, superior olive. c: Distribution of pontine-lumbospinal NA neurons expressing c-fos following the formalin test. Although the majority of
c-fos-positive neurons were located in LC the proportional distribution was relatively even across the cell groups (A5, 21%, LC, 16%, and A7,
26%, n  8). Scale bars  100 m.
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tooth pulp stimulation (Voisin et al., 2005). Tachykinin receptor
antagonists attenuated both the behavioral and increased LC
c-fos responses to formalin, suggesting that the LC neurons
are nociresponsive (Baulmann et al., 2000). Indeed, this in-
crease in LC c-fos expression has been suggested to be a
marker of the activation of the descending antinociceptive
control system (Tsuruoka et al., 2003). Our study demon-
strates that the pontine-lumbospinal NA neurons express
c-fos suggesting that they are activated during the formalin
test. This ﬁnding is similar to that reported by Voisin et al.
(2005), who showed c-fos expression in LC neurons projecting
to the somatosensory (VPL) thalamus after electrical tooth
pulp stimulation. It is interesting to note that some of our
pontospinal neurons were shown to also project to the so-
matosensory thalamus and thus may be capable of exerting a
coordinated, multilevel regulatory inﬂuence on noxious trans-
mission. We have also shown that similar proportions of pon-
tospinal neurons are activated across all three of the norad-
renergic cell groups (A5, LC, and A7). This suggests that they
all make a contribution to the response, but it remains to be
determined whether they are exerting similar effects, acting
cooperatively via different mechanisms or whether they pro-
duce antagonistic effects.
In summary, we have demonstrated the use of an AVV to
effectively and selectively target the neurons of the noradren-
ergic pontospinal projection to the lumbar dorsal horn. We
show that these neurons form a subgroup (<5%) of the total
pool of pontine NA neurons and that their spinal projection
has a distinct rostrocaudal topology. We show that at least
some of the LC pontospinal neurons project to other regions
in the brainstem and higher centers, which are recognized as
part of the pain matrix providing the substrate for a multilevel
response to noxious inputs. Finally, we show that these neu-
rons are activated in response to a persistent noxious stimu-
lus indicating that they are likely to be a component of the
endogenous analgesic system. There is good evidence that
this NA system is involved in the control of pain and nocicep-
tive behaviors (Millan, 2002; Pertovaara, 2006), pharmacolog-
ical manipulation of this system is useful in the treatment of
both acute and chronic pain (Eisenach et al., 1995; Sindrup
and Jensen, 1999) and there is evidence of dysregulation this
system in models of neuropathic pain (Ma and Eisenach,
2003). Using this type of viral vector targeting of the ponto-
spinal neurons we may in principle be able to express gene
products (e.g., ion channels) to manipulate the activity of
noradrenergic neurons to suppress pain signals originating
from a particular spinal level, such as those associated with
certain severe neuropathic pains such as postherpetic neu-
ralgia or following spinal cord injury.
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